Lorcaserin, A 5-HT2CReceptor Agonist, Reduces Body Weight by Decreasing Energy Intake without Influencing Energy Expenditure | Zendy

Corby K. Martin | Zendy; Leanne M. Redman | Zendy; Jinkun Zhang | Zendy; Matilde Sanchez | Zendy; Christen M. Anderson | Zendy; Steven R. Smith | Zendy; Éric Ravussin | Zendy

Open Access

Lorcaserin, A 5-HT_2CReceptor Agonist, Reduces Body Weight by Decreasing Energy Intake without Influencing Energy Expenditure

Author(s) -

Corby K. Martin,

Leanne M. Redman,

Jinkun Zhang,

Matilde Sanchez,

Christen M. Anderson,

Steven R. Smith,

Éric Ravussin

Publication year - 2010

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2010-1848

Subject(s) - placebo , respiratory quotient , medicine , overweight , endocrinology , appetite , body mass index , weight loss , obesity , agonist , crossover study , zoology , receptor , biology , alternative medicine , pathology

Lorcaserin, a selective 5-hydroxytryptamine (5-HT)(2C) receptor agonist, reduces body weight. It is unclear whether weight loss is due to reduced energy intake (EI) or also to enhanced energy expenditure (EE).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research